
|Articles|September 1, 2003
Allergy drug efficacy confirmed at molecular level
Fort Lauderdale, FL-Olopatadine hydrochlo-ride ophthalmic solution (Patanol, Alcon) reduces the release of mast-cell-derived mediators and their allergic effects in the eyes of patients with allergic conjunctivitis, according to Andrea Leonardi, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
3
Neurotrophic keratitis outcomes improve with early, stage-based care
4
Alcon raises offer in amended deal to acquire STAAR Surgical
5













































.png)


